secwatch.observer — SEC 8-K summary
======================================

Issuer:     Whitehawk Therapeutics, Inc. (WHWK)
CIK:        0001422142
Form:       8-K
Filed at:   2026-03-12T23:59:59+00:00
Accession:  0001193125-26-103117
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Whitehawk reports FY2025 net loss $20.6M (incl $87.3M gain); cash $145.7M, two Phase 1 ADCs
--------------------------------------------------------------------------------

- FY2025 net loss $20.6M includes $87.3M gain on AADI divestiture; Q4 net loss $23.3M vs $18.3M prior-year quarter.
- Cash, equivalents and ST investments $145.7M at YE2025 (up from $47.2M); cash runway into 2028.
- HWK-007 (PTK7) and HWK-016 (MUC16) ADCs both actively recruiting Phase 1 trials in lung, ovarian, endometrial cancers.
- HWK-206 IND submission for small-cell lung cancer and neuroendocrine tumors planned mid-2026; Phase 1 start Q3 2026.
- Margaret Dugan appointed CMO in December 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1422142/000119312526103117/0001193125-26-103117-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1422142/000119312526103117/whwk-20260312.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-103117

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer